Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-NeoB
- Development stage
- Unknown
- Lead developer
- Advanced Accelerator Applications
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
177Lu-NeoB (AAA603) is a Gastrin-Releasing Peptide Receptor (GRPR)-targeted radioligand therapy (RLT) developed by Advanced Accelerator Applications, a Novartis company. The drug consists of a high-affinity bombesin-derived peptide antagonist (NeoB) conjugated to the beta-emitting radioisotope Lutetium-177 (177Lu). GRPR is a G-protein coupled receptor frequently overexpressed in several solid tumors, including breast, prostate, and lung cancers. Upon intravenous administration, 177Lu-NeoB binds specifically to GRPR-expressing tumor cells, where the 177Lu isotope delivers localized ionizing radiation, inducing DNA double-strand breaks and subsequent apoptosis. It is currently being evaluated in Phase 1/2 clinical trials for the treatment of advanced solid tumors, with a particular focus on GRPR-positive breast cancer.
- Other names
- [177Lu]Lu-NeoB177Lu-NeoBOMB1lutetium (177Lu) neobombesin
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on 177Lu-NeoB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-NeoB.